Stryker (NYSE:SYK) Downgraded by Wall Street Zen to Hold

Stryker (NYSE:SYK) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other research firms also recently commented on SYK. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Wells Fargo & Company lifted their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a research note on Friday, November 14th. Truist Financial boosted their price objective on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a report on Friday, November 14th. Barclays raised their target price on Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, BTIG Research reiterated a “buy” rating and set a $410.00 price target on shares of Stryker in a report on Friday, November 14th. Twelve research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $431.83.

Stryker Stock Up 0.3%

SYK stock opened at $353.99 on Friday. The stock’s 50 day simple moving average is $366.81 and its 200 day simple moving average is $378.50. The company has a market cap of $135.37 billion, a P/E ratio of 46.52, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.13 and a current ratio of 1.85. Stryker has a fifty-two week low of $329.16 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the previous year, the company posted $2.87 earnings per share. The company’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, research analysts expect that Stryker will post 13.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Stryker

In related news, CFO Preston Wendell Wells sold 165 shares of the business’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total value of $60,370.20. Following the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the sale, the chief accounting officer owned 2,833 shares of the company’s stock, valued at $1,035,433.17. This trade represents a 40.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 522,118 shares of company stock worth $185,381,932 in the last quarter. 5.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Mid American Wealth Advisory Group Inc. purchased a new position in Stryker in the second quarter valued at approximately $26,000. Clayton Financial Group LLC bought a new stake in shares of Stryker in the third quarter valued at $26,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Stryker during the 2nd quarter valued at $28,000. Sachetta LLC grew its stake in shares of Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 27 shares during the period. Finally, Kilter Group LLC purchased a new stake in Stryker in the 2nd quarter worth about $29,000. 77.09% of the stock is owned by institutional investors.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.